Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 6/20 | 0.34 |
| ▸ | METTL3 | Q86U44 | 4/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.34 |
| ▸ | DUT | P33316 | 1/20 | 0.32 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17106744 | 0.92 | NT5E (0.38) | TOP2AMETTL3PRMT5DUT | |
| SCHEMBL17106805 | 0.92 | DUT (0.33) | TOP2AMETTL3PRMT5DUT | |
| SCHEMBL17111270 | 0.92 | NT5E (0.38) | TOP2AMETTL3PRMT5DUT | |
| SCHEMBL17111296 | 0.92 | NT5E (0.38) | TOP2AMETTL3PRMT5DUT | |
| SCHEMBL17106716 | 0.87 | PRMT5 (0.43) | METTL3PRMT5 | |
| SCHEMBL17106711 | 0.81 | PDE4D (0.45) | METTL3PRMT5POLB | |
| SCHEMBL17106837 | 0.81 | POLB (0.36) | METTL3PRMT5POLB | |
| SCHEMBL734839 | 0.80 | POLB (0.46) | TOP2ADUTPOLB | |
| SCHEMBL11986900 | 0.80 | POLB (0.46) | TOP2ADUTPOLB | |
| SCHEMBL21317432 | 0.80 | POLB (0.46) | TOP2ADUTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180002366-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-01-04 | — | — | US | disclosed |
| US-9777035-B2 | 4′-substituted nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-10-03 | — | — | US | disclosed |
| EP-3122752-A1 | 4'-SUBSTITUTED NUCLEOSIDE-DERIVATIVES AS HIV REVERSE TRANSCRIPTASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-02-01 | — | — | EP | disclosed |
| US-20150274767-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | US | disclosed |
| WO-2015148746-A1 | 4'-SUBSTITUTED NUCLEOSIDE-DERIVATIVES AS HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | WO | disclosed |
| WO-2015143712-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002366-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | DUT, HPRT1, RNGTT | TOP2A 280/4885METTL3 624/4885PRMT5 151/4885 |
| US-20150274767-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | DUT, HPRT1, RNGTT | TOP2A 280/4885METTL3 624/4885PRMT5 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.